Loading...
•
Jun 30, 2023
Anika Q2 2023 Earnings Report
Anika reported double-digit revenue growth and improved margins, driven by a 22% increase in OA Pain Management revenue.
Key Takeaways
Anika Therapeutics reported strong second-quarter results, with double-digit revenue growth driven by OA Pain Management. The company is making significant progress with its Hyalofast Phase III trial and advancing the development of Integrity. Anika updated its full-year revenue outlook to $159.5 million to $163 million.
Anika reported double-digit top line growth and improved margins in Q2 2023.
The Phase III Pivotal study for Hyalofast is fully enrolled and on track for modular PMA filing.
Development of Integrity, the HA-based rotator cuff patch system, remains on track for a 2024 launch.
RevoMotion™ Reverse Shoulder full market release accelerated to September 2023.
Forward Guidance
Anika expects full-year 2023 revenue to be between $159.5 million and $163 million, representing growth of 2% to 4% compared to 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...